FDA Risk “Concept Papers” Expected In March; April Workshop Set
FDA hopes to release three "concept papers" on risk assessment and risk management March 10 as the first step in developing risk guidances mandated under the Prescription Drug User Fee Act reauthorization
More from Archive
More from Pink Sheet
Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.
At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.
CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.